2008
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Herbst RS, Sandler A. Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. The Oncologist 2008, 13: 1166-1176. PMID: 18997180, DOI: 10.1634/theoncologist.2008-0108.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerF. Hoffmann-La Roche LtdEpidermal growth factor receptorAdvanced non-small cell lung cancerTumor growthRandomized phase II trialRecombinant humanized monoclonal antibodyHuman epidermal growth factor receptorCombination of bevacizumabPhase II trialSelective tyrosine kinase inhibitorAdditional clinical benefitSecond-line alternativeCell lung cancerPotential predictive markerHumanized monoclonal antibodyVascular endothelial growth factorTyrosine kinase inhibitorsSouth San FranciscoEndothelial growth factorGrowth factor receptorAdvanced diseaseErlotinib monotherapyII trialProspective trial
2000
Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
Kris M, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, Feyereislova A, Ochs J, Averbuch S. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 2000, 29: 72. DOI: 10.1016/s0169-5002(00)80233-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorNon-small cell lung cancer patientsCell lung cancer patientsPhase I trialSelective tyrosine kinase inhibitorLung cancer patientsTyrosine kinase inhibitorsGrowth factor receptorObjective regressionI trialCancer patientsOral ZD1839Kinase inhibitorsFactor receptorPatientsZD1839